(Q34756501)

English

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

opportunistic infection

1 reference

based on heuristic

inferred from title

Jeffrey R Curtis

14

object named as

Jeffrey R Curtis

1 reference

Europe PubMed Central

4 August 2017

Carlos G. Grijalva

5

object named as

Carlos G Grijalva

1 reference

Europe PubMed Central

4 August 2017

Daniel H Solomon

12

object named as

Daniel H Solomon

1 reference

Europe PubMed Central

4 August 2017

13

object named as

James D Lewis

1 reference

Europe PubMed Central

4 August 2017

Kevin L Winthrop

2

object named as

Kevin L Winthrop

1 reference

Europe PubMed Central

4 August 2017

Elizabeth Delzell

6

object named as

Elizabeth Delzell

1 reference

Europe PubMed Central

4 August 2017

10

object named as

Kenneth G Saag

1 reference

Europe PubMed Central

4 August 2017

Timothy Beukelman

7

object named as

Timothy Beukelman

1 reference

Europe PubMed Central

4 August 2017

Lisa J Herrinton

11

object named as

Lisa J Herrinton

1 reference

Europe PubMed Central

4 August 2017

author name string

John W Baddley

1

1 reference

Europe PubMed Central

4 August 2017

Lang Chen

3

1 reference

Europe PubMed Central

4 August 2017

Liyan Liu

4

1 reference

Europe PubMed Central

4 August 2017

Nivedita M Patkar

8

1 reference

Europe PubMed Central

4 August 2017

Fenglong Xie

9

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

13 July 2013

1 reference

Europe PubMed Central

4 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

4 August 2017

73

1 reference

Europe PubMed Central

4 August 2017

11

1 reference

Europe PubMed Central

4 August 2017

1942-1948

1 reference

Europe PubMed Central

4 August 2017

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Geographic distribution of endemic fungal infections among older persons, United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Infectious complications of tumor necrosis factor blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4273901

7 July 2018

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Veteran's affairs hospital discharge databases coded serious bacterial infections accurately

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Preventing and treating biologic-associated opportunistic infections.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- Antagonists

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203407

21 January 2018

Antirheumatic drugs and the risk of tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pneumocystis pneumonia associated with infliximab in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of latent granulomatous infections by infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852763

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2013-203407

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34756501&oldid=2075941285"